For example, approximately 20–30% of infiltrative gliomas carry mutations in isocitrate dehydrogenase 1 (IDH1) or, far less commonly, IDH2 (together referred to as “IDHmut”) [7–9]. This evidence concerns the gene IDH2 and central nervous system cancer.